Core Insights - The company Garden Biologics announced that its wholly-owned subsidiary, Garden Pharmaceuticals, has won the bid for the 11th batch of national centralized drug procurement for its product Alendronate Sodium Tablets [1] - This medication is primarily used for the treatment of osteoporosis in postmenopausal women and men to increase bone mass [1] - The product specifications are 70mg per tablet, with each box containing 4 tablets, and the procurement regions include Inner Mongolia, Jiangsu, Henan, Hunan, and Gansu, with a procurement period lasting until December 31, 2028 [1] Market Impact - Winning this bid will help the product rapidly expand its market presence and increase market share [1] - It will promote the development of the company's pharmaceutical formulation business and further enrich the company's product pipeline [1] - This achievement is expected to enhance the company's brand influence in the industry [1]
花园生物:子公司产品中选国家药品集采